WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• WAVE Life Sciences has a “Moderate Buy” consensus rating from 16 brokerages, with 14 buy ratings, one strong-buy, and one sell. The average 12-month price target is $22.53, compared with the stock’s reported $6.10 opening price.
• Institutional investors own approximately 89.73% of WAVE’s outstanding shares, with several firms significantly increasing their positions during recent quarters.
• WAVE reported a quarterly loss of $0.34 per share, missing the $0.30 consensus estimate, while revenue of $2.27 million fell well short of the $7.45 million forecast. The company remains unprofitable, with a negative net margin of 309.73%.

WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the sixteen brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, fourteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $22.5294.

A number of brokerages recently commented on WVE. New Street Research set a $13.00 price objective on shares of WAVE Life Sciences in a research note on Thursday, June 11th. Truist Financial started coverage on WAVE Life Sciences in a report on Wednesday, April 29th. They issued a "buy" rating and a $15.00 price target on the stock. Canaccord Genuity Group decreased their price objective on WAVE Life Sciences from $52.00 to $43.00 and set a "buy" rating for the company in a research note on Thursday, April 30th. Zacks Research raised WAVE Life Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 21st. Finally, Citigroup reduced their target price on shares of WAVE Life Sciences from $24.00 to $19.00 and set a "buy" rating for the company in a report on Friday, July 31st.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of WVE. CWM LLC increased its position in shares of WAVE Life Sciences by 6,729.0% during the fourth quarter. CWM LLC now owns 2,117 shares of the company's stock worth $36,000 after purchasing an additional 2,086 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in shares of WAVE Life Sciences by 645.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company's stock worth $38,000 after purchasing an additional 1,942 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of WAVE Life Sciences in the 4th quarter worth $82,000. Mirae Asset Global Investments Co. Ltd. grew its stake in WAVE Life Sciences by 32.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,124 shares of the company's stock worth $138,000 after buying an additional 1,972 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in WAVE Life Sciences by 1,441.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company's stock worth $73,000 after buying an additional 9,284 shares during the last quarter. Institutional investors own 89.73% of the company's stock.

WAVE Life Sciences Stock Performance

NASDAQ:WVE opened at $6.10 on Monday. WAVE Life Sciences has a one year low of $5.02 and a one year high of $21.73. The firm has a market cap of $1.20 billion, a P/E ratio of -5.60 and a beta of -1.26. The firm has a 50-day simple moving average of $5.93 and a 200-day simple moving average of $8.66.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.04). The business had revenue of $2.27 million for the quarter, compared to the consensus estimate of $7.45 million. WAVE Life Sciences had a negative net margin of 309.73% and a negative return on equity of 50.36%. On average, research analysts predict that WAVE Life Sciences will post -1.12 EPS for the current fiscal year.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company's pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington's disease, as well as early-stage cardiovascular and liver indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source